Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Du bruger tilsyneladende en bredere skærm. Vil du gerne give denne side en bredere visningsoplevelse?

BioPorto - Receives FDA clearance for NGAL test in the US

Af HC Andersen Capital
BioPorto

Meet and ask questions to CEO Tony Paré from Bioporto on 11 December at 13:00 CET.

The focus will be on FDA 510(k) clearance for the NGAL test in the United States. This is the first test to aid in assessing AKI (Acute Kidney Injury) risk for patients aged 3 months through 21 years. The test will be marketed as ProNephro AKI™ (NGAL). Bioporto expects that US sales through its distribution agreement with Roche Diagnostics GmbH will begin in the second half of 2024.

Disclaimer: HC Andersen Capital receives payment from Bioporto for a DigitalIR/Corporate Visibility and IR advisory agreement./Claus Thestrup 13:05 8/12-2023.

Seneste videoer

AKTIER MED FRIIS - UGE 49 2025
05.12.2025, 12.00
HCA Morgenbørs 05/12 - Overvejende positive futures-markeder hvor kun Japan er i minus
05.12.2025, 09.20 GreenMobility
GreenMobility: What is the investment case in driverless cars
05.12.2025, 08.00 GreenMobility
UPM and Sappi are planning a joint venture in graphic papers
04.12.2025, 13.00 UPM-Kymmene
GreenMobility: How far away are driverless cars in Denmark
04.12.2025, 11.32 GreenMobility
Vis alle videoer
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.